AN OBSERVATIONAL STUDY OF AVASTIN® (BEVACIZUMAB) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER (OSCAR 1)

Study identification

• EU PAS number:
  EUPAS10394
• Study ID:
  44667
• Official title and acronym:
  AN OBSERVATIONAL STUDY OF AVASTIN® (BEVACIZUMAB) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER (OSCAR 1)
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  Multi-centre, observational (non-interventional) study to follow patients with aOC, who have received no previous treatment for advanced disease and are receiving or have received Avastin in combination with a standard of care first line chemotherapy regimen.
• Study status:
  Finalised

Research institutions and networks

Institutions

Multiple centres: 30 centres are involved in the study

Study timelines

Date when funding contract was signed

Actual: 18/03/2013

Study start date

Actual: 10/05/2013

Date of final study report

Actual: 15/06/2018

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Roche

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

ML28570